Abstract 2282P
Background
The immune system can eliminate malignancy by identifying antigenic peptide epitope presented by neoplastically transformed cells. Immune cells recognize abnormal glycosylation on cancer cells, and this recognition often leads to an inhibitory immune process. We designed a biomedical study to evaluate the role of tissue glycan in predicting immunotherapy response in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).
Methods
Thirty-two patients with intermediate/poor risk RCC and advanced HCC (eight respondents and eight non-respondents each) who had received first line immunotherapy-based therapy were identified. The overall survival for RCC and HCC non-respondent cohort was 27.9 months and 8 months respectively but was immature for the respondent cohort. Response criteria to immunotherapy was decided based on the immune related response criteria (iRECIST) where good response is defined as complete or partial response while poor respondent was defined as progression of disease with median survival shorter than reported. Next, we compare the relative abundance and spatial distribution of the glycans in the responder versus non-responder tissue sections given regional characterizations within the tissues. This helps points out the distinct glycans between the responder versus non-responder tissue sections that could serve as potential biomarkers which can then be used in future diagnostic and/or therapeutic intervention. We used the MALDI analysis by rapifleX.
Results
MALDI imaging of HCC and RCC responder versus non-responder tissue section was successfully demonstrated. There was distinct responder versus non responder glycan markers demonstrated by unsupervised segmentation analysis, showing specific layers of glycan organization in the different tissue regions. There are several glycan peaks showing distinctive expression between respondent versus non respondent patients. PCA showed distinguishable variances across each annotated structures derived from segmentation analysis.
Conclusions
Distinct glycan profile markers were observed between both responder and non-responder cohort showing specific layers of glycan organization in the different tissue regions.
Clinical trial identification
NHG DSRB Ref: 2021/01072
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
NMC CG program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262P - Baseline-informed versus tumor-agnostic minimal residual disease (MRD) concordance study in patients with HER2+ gastroesophageal adenocarcinoma patients
Presenter: Pan Du
Session: Poster session 08
2263P - Ethnicity-specific distribution of BRCA1, BRCA2, PALB2 and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus
Presenter: Evgeny Imyanitov
Session: Poster session 08
2264P - Proteomics-based phenotypic classification of non-smallcell lung cancer
Presenter: Olena Berkovska
Session: Poster session 08
2265P - miR-4487 enhances gefitinib-mediated ubiquitination and autophagic degradation of EGFR in non-small cell lung cancer cells by targeting USP37
Presenter: Sei-Hoon Yang
Session: Poster session 08
2266P - IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort
Presenter: Marie Morfouace
Session: Poster session 08
2267P - Coronary heart disease and risk of lung cancer: A two-sample Mendelian randomization study
Presenter: Cai Chen Li
Session: Poster session 08
2269P - Patient derived xenografts generated from circulating cancer stem cells on chorioallantoic membrane as an alternative pre-clinical model for personalized medicine in pancreatic cancer
Presenter: Monika Pizon
Session: Poster session 08
2270P - Integrative analyses of bulk and single-cell RNA-seq identified diabetes mellitus-related signature as a prognostic factor in pancreatic adenocarcinoma
Presenter: Le Tang
Session: Poster session 08
2271P - Development of an oncolytic virus for the treatment of high grade serous ovarian cancer and other stromal rich tumours
Presenter: Miriam Bazan Peregrino
Session: Poster session 08
2272P - Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)
Presenter: Matteo Benelli
Session: Poster session 08